© 2004 European Society for Medical Oncology
Original Article |
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer
Departments of 1 Medical Oncology and 2 Pathology, VU University Medical Center, Amsterdam, The Netherlands
* Correspondence to: Professor G. Giaccone, Division of Medical Oncology, Academic Hospital Vrije Universiteit, 1117 De Boelelaan, HV 1081 Amsterdam, The Netherlands. Tel: +31-20-4444352; Fax: +31-20-4444079; Email: g.giaccone{at}vumc.nl
Background: Expression of survivin, a member of the inhibitor of apoptosis protein family, is commonly detected in cancers but not in normal differentiated tissues. Survivin is usually localized in the cytoplasm of cancer cells, but nuclear localization has also been described, and we recently reported that survivin is a nuclear–cytoplasmic shuttling protein.
Patients and methods: Fifty-three tumor specimens from patients with inoperable non-small-cell lung cancer (NSCLC) (55% stage IIIA, 17% stage IIIB and 28% stage IV) who underwent chemotherapy treatment were evaluated with immunohistochemistry for survivin expression and localization. These two sets of data were processed and tested for correlation with major patient characteristics, response to chemotherapy, and overall and relapse-free survival.
Results: Survivin was present only in malignant tissues, and 47/53 (89%) of the specimens were positive. The overall median expression of tumor cells was 40%, and this value was used as a cut-off point for statistical analysis. By dichotomizing the specimens as expressing low or high levels of survivin, a significant association was seen between the expression of survivin and the histology of the tumors (P=0.020), squamous cell carcinoma being the histotype with lower levels of survivin expression. Three patterns of localization were observed: 42% of cases (22/53) showed reactivity confined to the nucleus, 17% (nine of 53) only in the cytoplasm and 30% (16/53) in both the nucleus and the cytoplasm. Interestingly, nuclear survivin levels predicted longer overall and relapse-free survival, in univariate and multivariate analyses. Expression and localization of survivin did not correlate with response to chemotherapy.
Conclusions: Our results indicate that differential localization of survivin may be a prognostic factor for NSCLC. Further studies are warranted.
Key words: inhibitors of apoptosis, non-small-cell lung cancer, nuclear localization, survivin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Mohamed, K. Yasufuku, T. Nakajima, K. Hiroshima, M. Chiyo, S. Yoshida, M. Suzuki, Y. Sekine, K. Shibuya, G. Agamy, et al. Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Eur. Respir. J., January 1, 2009; 33(1): 127 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Angell A study into the potential role of Survivin localization in resistance to drug-induced apoptosis Bioscience Horizons, June 1, 2008; 1(2): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Knauer, O. H. Kramer, T. Knosel, K. Engels, F. Rodel, A. F. Kovacs, W. Dietmaier, L. Klein-Hitpass, N. Habtemichael, A. Schweitzer, et al. Nuclear export is essential for the tumor-promoting activity of survivin FASEB J, January 1, 2007; 21(1): 207 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vischioni, J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol. Cancer Ther., November 1, 2006; 5(11): 2905 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fukuda and L. M. Pelus Survivin, a cancer target with an emerging role in normal adult tissues Mol. Cancer Ther., May 1, 2006; 5(5): 1087 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mao, M. C. Fishbein, B. Adams, M. D. Roth, L. Goodglick, L. Hong, M. Burdick, E. R. M. Strieter, C. Holmes, D. P. Tashkin, et al. Celecoxib Decreases Ki-67 Proliferative Index in Active Smokers Clin. Cancer Res., January 1, 2006; 12(1): 314 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cecchin, G. Corona, S. Masier, P. Biason, G. Cattarossi, S. Frustaci, A. Buonadonna, A. Colussi, and G. Toffoli Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients Clin. Cancer Res., October 1, 2005; 11(19): 6901 - 6907. [Abstract] [Full Text] [PDF]
|
|